Texas OB/GYN: My Existence Is In Violation Of The New Abortion Law
By Michel Martin,
NPR
| 08. 29. 2021
Photo by Do512 on Flickr
Ahead of Texas' abortion ban going into effect on Sept. 1, NPR's Michel Martin speaks with Dr. Ghazaleh Moayedi, an OB/GYN, about what it means for abortion providers and patients there.
MICHEL MARTIN, HOST:
Texas has passed one of the nation's most restrictive abortion bans, and it is just days from becoming law. Barring legal challenges, Senate Bill 8 is set to go into effect on Wednesday. The law signed by Governor Greg Abbott this spring bans abortions as early as six weeks after conception and allows Texans to sue anyone who aids, abets or performs an abortion past that mark. There are no exemptions for cases involving rape or incest.
Doctors and other medical providers around the state have been outspoken in their opposition to the bill. In May, more than 200 Texas physicians signed an open letter saying the bill could, quote, "place physicians at risk of frivolous lawsuits that threaten our ability to provide health care in Texas," unquote. Dr. Ghazaleh Moayedi is one of those who signed the letter. She is...
Related Articles
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...